ArticleTransplantation and cellular therapy2026
Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.
Kitsada Wudhikarn et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.